Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Non-small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Not applicableNo Longer AvailableNCT05100134
What this trial is testing

Managed Access Programs for LDK378, Ceritinib

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT03737994
What this trial is testing

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
National Cancer Institute (NCI) 10
Testing effectiveness (Phase 2)Study completedNCT04318938
What this trial is testing

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Who this might be right for
NSCLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 118
Not applicableEnded earlyNCT02228421
What this trial is testing

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
PeriPharm 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Looking for participantsNCT05713006
What this trial is testing

Alectinib Pharmacokinetic in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIIBALK Gene Mutation
Instituto Nacional de Cancerologia de Mexico 45
Testing effectiveness (Phase 2)Study completedNCT01752400
What this trial is testing

AUY922 for Advanced ALK-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 6
Testing effectiveness (Phase 2)Study completedNCT03088930
What this trial is testing

Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Nonsmall Cell
University of Colorado, Denver 3
Testing effectiveness (Phase 2)Ended earlyNCT03666728
What this trial is testing

SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Who this might be right for
Lung Neoplasms
Jiangsu HengRui Medicine Co., Ltd. 5
Large-scale testing (Phase 3)Looking for participantsNCT05236946
What this trial is testing

Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT

Who this might be right for
Asymptomatic Brain MetastasesDriver Mutation Positive Non-small Cell Lung Cancer
Tata Memorial Hospital 190
Testing effectiveness (Phase 2)Study completedNCT02450903
What this trial is testing

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Who this might be right for
Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals 20
Not applicableActive Not RecruitingNCT05735327
What this trial is testing

Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 50
Testing effectiveness (Phase 2)UnknownNCT05801107
What this trial is testing

Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 30
Testing effectiveness (Phase 2)Ended earlyNCT03131206
What this trial is testing

Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Who this might be right for
ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
Dana-Farber Cancer Institute 5
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Post-approval studies (Phase 4)Not Yet RecruitingNCT07671560
What this trial is testing

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

Who this might be right for
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Qiming Wang 80
Testing effectiveness (Phase 2)UnknownNCT04415320
What this trial is testing

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall CellBrain Metastases
Betta Pharmaceuticals Co., Ltd. 37
Testing effectiveness (Phase 2)WithdrawnNCT06522360
What this trial is testing

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Who this might be right for
Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Next Page